← Back to Patent Explorer
US4359476A Expired / Lapsed US ⏱️ 0.0 years remaining

Adjacently substituted cycloalkane-amide analgesics

Assignee: Pharmacia and Upjohn Co
•
Filing: 1981-04-09
•
Granted: 1982-11-16
•
Expires: 2001-04-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract N-[2-Amino(oxy or thio group) substituted-cycloaliphatic]phenylacetamide and -benzamide compounds, having the oxy- or thio group substituents on a cycloaliphatic ring carbon adjacent to either of the nitrogen bearing carbons of the cycloaliphatic ring, e.g., cis- and trans-4-bromo-N-[3-methoxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methylbenzamide, and trans-3,4-dichloro-N-methyl-N-[7-(1-pyrridolinyl)-1,4-dioxaspiro[4.5]dec-6-yl]benzeneacetamide, and salts thereof, have useful analgesic activity and low abuse liability in humans and valuable warm blooded animals. Processes for their production and pharmaceutical compositions and method of use are also disclosed.

Inventors

  • 👤 Lester J. Kaplan
  • 👤 Moses W. McMillan
  • 👤 Jacob Szmuszkovicz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 21:33
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/12; C07D295/135; A; A61; A61P; A61P25/00; A61P25/04; C07D317/00; C07D317/08; C07D317/72; C07D327/00; C07D327/02; C07D327/06; C07D491/00; C07D491/02; C07D491/10; C07D493/00; C07D493/02; C07D493/10; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804

Claims Analysis

Total Claims: 22
Claim 1
Independent Claim 358 words
A compound of the formula wherein: R is hydrogen or C 1 to C 3 -alkyl; R 1 and R 2 , taken separately, are each hydrogen or C 1 to C 3 -alkyl; R 1 and R 2 , taken together with the nitrogen to which they are bonded, are azetidinyl, pyrrolidinyl or piperidinyl; R 3 , taken separately, is hydroxy, C 1 to C 2 -alkyloxy, or C 1 to C 3 -alkanoyloxy; R 4 , taken separately, is hydrogen when R 3 is hydroxy, C 1 to C 2 -alkyloxy,or C 1 to C 3 -alkanoyloxy; R 3 and R 4 , taken together, complete a moiety selected from the group, ═G (oxo or thioxo), --G--CH 2 CH 2 --G--, --G--CH 2 CH 2 CH 2 --G--, --G--CH 2 CH(CH 3 )CH 2 --G--, --G--CH 2 C(CH 3 ) 2 CH 2 --G--, wherein both G moieties in the same group are oxygen or bivalent sulfur, ═N˜OH, and ═N˜OC(═O)CH 3 , wherein each G is oxygen or bivalent sulfur; X and Y are independently selected from the group consisting of hydrogen, a halogen having an atomic number from 9 to 35, trifluoromethyl, nitro, methoxy, hydroxy, azido, C 1 to C 3 -alkyl, phenyl, methanesulfonyl, cyano, amino, C 1 to C 3 -alkoxycarbonyl, C 1 to C 3 -alkanoyloxy, C 1 to C 3 -carboxacylamino(--NHC(═O)R 6 , wherein R 6 is hydrogen or C 1 to C 2 -alkyl); p and n are whole number integers selected from the group zero, 2, 3, or 4 such that one of p and n is zero and the other of p and n is 2, 3, or 4; q is zero or 1; E is oxygen or bivalent sulfur; provided that when R is C 1 to C 3 -alkyl, R 1 and R 2 taken together with the nitrogen to which they are bonded complete a pyrrolidinyl ring, p is 3 and n is 0, q is 1, X and Y are chlorine in the 3 and 4 positions, R 3 is not hydroxy, C 1 to C 2 -alkoxy or C 1 to C 3 -alkanoyloxy;
Claim 2
Dependent Claim 358 words
A compound of the formula wherein: R is hydrogen or C 1 to C 3 -alkyl; R 1 and R 2 , taken separately, are each hydrogen or C 1 to C 3 -alkyl; R 1 and R 2 , taken together with the nitrogen to which they are bonded, are azetidinyl, pyrrolidinyl or piperidinyl; R 3 , taken separately, is hydroxy, C 1 to C 2 -alkyloxy, or C 1 to C 3 -alkanoyloxy; R 4 , taken separately, is hydrogen when R 3 is hydroxy, C 1 to C 2 -alkyloxy,or C 1 to C 3 -alkanoyloxy; R 3 and R 4 , taken together, complete a moiety selected from the group, ═G (oxo or thioxo), --G--CH 2 CH 2 --G--, --G--CH 2 CH 2 CH 2 --G--, --G--CH 2 CH(CH 3 )CH 2 --G--, --G--CH 2 C(CH 3 ) 2 CH 2 --G--, wherein both G moieties in the same group are oxygen or bivalent sulfur, ═N˜OH, and ═N˜OC(═O)CH 3 , wherein each G is oxygen or bivalent sulfur; X and Y are independently selected from the group consisting of hydrogen, a halogen having an atomic number from 9 to 35, trifluoromethyl, nitro, methoxy, hydroxy, azido, C 1 to C 3 -alkyl, phenyl, methanesulfonyl, cyano, amino, C 1 to C 3 -alkoxycarbonyl, C 1 to C 3 -alkanoyloxy, C 1 to C 3 -carboxacylamino(--NHC(═O)R 6 , wherein R 6 is hydrogen or C 1 to C 2 -alkyl); p and n are whole number integers selected from the group zero, 2, 3, or 4 such that one of p and n is zero and the other of p and n is 2, 3, or 4; q is zero or 1; E is oxygen or bivalent sulfur; provided that when R is C 1 to C 3 -alkyl, R 1 and R 2 taken together with the nitrogen to which they are bonded complete a pyrrolidinyl ring, p is 3 and n is 0, q is 1, X and Y are chlorine in the 3 and 4 positions, R 3 is not hydroxy, C 1 to C 2 -alkoxy or C 1 to C 3 -alkanoyloxy;
Claim 3
Dependent Claim 72 words
A compound according to claim 1, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete an N-pyrrolidinyl ring; R 3 is methoxy; R 4 is hydrogen; X is hydrogen; Y is a halogen having an atomic number of from 9 to 35; p is 3; n is 0; q is 0; E is oxygen;
Claim 4
Dependent Claim 11 words
A compound according to claim 2, wherein the compound is (1α,2β,3β)-4-bromo-N-[3-methoxy-2-(1-pyrrolidinyl)cyclohex
Claim 5
Dependent Claim 11 words
A compound according to claim 2, wherein the compound is (1α,2β,3α)-4-bromo-N-[3-methoxy-2-(1-pyrrolidinyl)cyclohe
Claim 6
Dependent Claim 77 words
A compound according to claim 1, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete an N-pyrrolidinyl ring; R 3 and R 4 are taken together to complete an ethylenedioxy ketal ring; X and Y are each halogen having an atomic number of from 9 to 35; p is zero; n is 3; q is 1; E is oxygen;
Claim 7
Dependent Claim 11 words
A compound according to claim 5, wherein the compound is trans-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-6-yl]benzeneacetamide,
Claim 8
Dependent Claim 70 words
A compound according to claim 1, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are each C 1 to C 3 -alkyl; R 3 and R 4 are taken together to complete an ethylenedioxy ketal group; X is hydrogen; Y is a halogen having an atomic number of from 9 to 35; p is 0; n is 3; q is 0; E is oxygen;
Claim 9
Dependent Claim 11 words
A compound according to claim 7, wherein the compound is trans-4-bromo-N-[7-(dimethylamino)-1,4-dioxaspiro[4.5]dec-6-yl]-N-methylbenzamide,
Claim 10
Dependent Claim 70 words
A compound according to claim 7, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are each C 1 to C 3 -alkyl; R 3 and R 4 are taken together to denote an ethylenedioxy ketal group; X and Y are each halogen atoms having an atomic number of from 9 to 35; p is 0; n is 3; q is 1; E is oxygen;
Claim 11
Dependent Claim 11 words
A compound according to claim 9, wherein the compound is trans-3,4-dichloro-N-[7-(dimethylamino)-1,4-dioxaspiro[4.5]dec-6-yl]-N-methylbenzeneacetamide,
Claim 12
Dependent Claim 80 words
A compound according to claim 1, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are taken together with the nitrogen to which they are attached to complete an N-pyrrolidinyl ring; R 3 and R 4 are taken together to complete an ethylenedioxy ring; X is a halogen having an atomic number of from 9 to 35 on the 4-position; Y is hydrogen; p is 3; n is 0; q is 0; E is oxygen;
Claim 13
Dependent Claim 11 words
A compound according to claim 11, wherein the compound is 4-bromo-N-methyl-N-[6-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-7-yl]benzamide;
Claim 14
Dependent Claim 80 words
A compound according to claim 1, wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete an N-pyrrolidinyl ring; R 3 and R 4 are taken together to denote an oxo function; X is a halogen having an atomic number of from 9 to 35 in the 4-position; Y is hydrogen; p is 3; n is 0; q is 0; E is oxygen;
Claim 15
Dependent Claim 11 words
A compound according to claim 13, wherein the compound is 4-bromo-N-methyl-N-[3-oxo-2-(1-pyrrolidinyl)cyclohexyl]benzamide,
Claim 16
Dependent Claim 19 words
A compound according to claim 1 wherein the compound is selected from the group consisting of 4-bromo-N-[3-hydroxy-2-(1-pyrrolidinyl)cyclohexyl]-N-methylbenzamide, 4-bromo-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-6-yl]benzamide, 4-bromo-N-[2-hydroxy-6-(1-pyrrolidinyl)cyclohexyl]-N-methylbenzamide,
Claim 17
Dependent Claim 21 words
A composition useful in pharmaceutically effective dosage unit form for alleviating pain in warm blooded mammals which comprises a compound of
Claim 18
Dependent Claim 21 words
A composition useful in pharmaceutically effective dosage unit form for alleviating pain in warm blooded mammals which comprises a compound of
Claim 19
Dependent Claim 95 words
A composition of claim 16 wherein the compound of claim 1 is a compound of the formula ##STR2## wherein R is C 1 to C 3 -alkyl; R 1 and R 2 are taken together with the nitrogen to which they are bonded to complete an N-pyrrolidinyl ring; R 3 and R 4 are taken together to complete an ethylenedioxy ketal ring; X and Y are each halogen having an atomic number of from 9 to 35; p is zero; n is 3; q is 1; E is oxygen; or a pharmaceutically acceptable salt thereof.
Claim 20
Dependent Claim 19 words
A composition of claim 17 wherein the compound of claim 1 is trans-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-6-yl]benzeneacetamide, or a pharmaceutically acceptable salt thereof.
Claim 21
Dependent Claim 28 words
A method for alleviating pain which comprises administering to an animal suffering pain an effective amount of a compound of claim 1 in a pharmaceutical dosage unit form.
Claim 22
Dependent Claim 19 words
A method of claim 19 wherein the compound of claim 1 is trans-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-6-yl]benzeneacetamide, or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

US3510492A Cited
US4065573A Cited
US4098904A Cited
US4145435A Cited
US4156733A Cited
US4212878A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-11-15 1986-05-17 1986-11-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-11-15 1990-05-17 1990-11-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-11-15 1994-05-17 1994-11-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag